Akèy › Blesi poumon egi
Etid klinik pou Blesi poumon egi ap rekrite nan Etazini
13 etid pou Blesi poumon egi ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Cleveland, OH5 etid
- New York City, NY5 etid
- Mountain View, CA5 etid
- Nashville, TN5 etid
- Durham, NC5 etid
- Seattle, WA5 etid
- Washington, DC5 etid
- Rochester, MN4 etid
- Sacramento, CA4 etid
- Edison, NJ4 etid
- Houston, TX4 etid
- The Bronx, NY4 etid
- Birmingham, AL4 etid
- Oklahoma City, OK4 etid
- Detroit, MI4 etid
- Orange, CA4 etid
- Somerville, MA4 etid
- Fort Worth, TX4 etid
- Long Beach, CA4 etid
- Peoria, IL4 etid
- Toledo, OH4 etid
- Boston, MA4 etid
- Boise, ID4 etid
- Sarasota, FL4 etid
- Ann Arbor, MI4 etid
- Gainesville, FL4 etid
- Charleston, SC4 etid
- Evanston, IL4 etid
- Charlottesville, VA4 etid
- St. Petersburg, FL4 etid
- Portland, OR4 etid
- Greenburgh, NY4 etid
- Denver, CO4 etid
- Fresno, CA4 etid
- West Jordan, UT4 etid
Pa eta
- Alabama4 etid
- Colorado4 etid
- Distrik Columbia4 etid
- Florid4 etid
- Idaho4 etid
- Illinois6 etid
- Kalifòni6 etid
- Massachusetts4 etid
- Michigan4 etid
- Minnesota5 etid
- New Jersey4 etid
- New York5 etid
- North Carolina5 etid
- Ohio5 etid
- Oklahoma4 etid
- Oregon4 etid
- Pennsylvania3 etid
- South Carolina4 etid
- Tennessee5 etid
- Texas4 etid
- Utah5 etid
- Virginia5 etid
- Washington5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Observational, Non-interventional Biomarker and Endotyping Study
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07675265Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 23, 2026 · NCT07613099Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 16, 2026 · NCT07449572Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06476132JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06703073JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06701656JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06701669JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06701682Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT06513949Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
Ap rekriteEtid obsèvasyon
Laj 21 a 90 · Tout sèks · Mizajou Jun 10, 2026 · NCT07125079Recovery of Physical Function After Critical Illness In Older Adults
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 99 · Tout sèks · Mizajou May 28, 2026 · NCT07225257Clinical Decision Support Tool in PARDS Pilot Study
Ap rekrite
1 Month – 18 Years · Tout sèks · Mizajou Apr 14, 2026 · NCT04068012This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT06853223Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.